<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/9C932CFE-AAE2-4A8F-A53F-1C7EAC961997"><gtr:id>9C932CFE-AAE2-4A8F-A53F-1C7EAC961997</gtr:id><gtr:name>Harvard University</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/2C711771-B8F6-4CDF-9AC3-9FAB317463D9"><gtr:id>2C711771-B8F6-4CDF-9AC3-9FAB317463D9</gtr:id><gtr:name>University of Cape Town</gtr:name><gtr:address><gtr:line1>Private Bag</gtr:line1><gtr:line2>Rondebosch</gtr:line2><gtr:postCode>7700</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>South Africa</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/A6E6C042-46F9-434B-970F-5F9C8BCF6F1A"><gtr:id>A6E6C042-46F9-434B-970F-5F9C8BCF6F1A</gtr:id><gtr:name>PENTA Foundation</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/B8315305-3AE0-4833-BCEF-0539D3B31074"><gtr:id>B8315305-3AE0-4833-BCEF-0539D3B31074</gtr:id><gtr:name>Gilead</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/FA687C0B-0BA5-416F-9706-CC09EE9C9AB5"><gtr:id>FA687C0B-0BA5-416F-9706-CC09EE9C9AB5</gtr:id><gtr:name>Paediatric Emergency Research in the United Kingdom &amp; Ireland (PERUKI)</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/9C932CFE-AAE2-4A8F-A53F-1C7EAC961997"><gtr:id>9C932CFE-AAE2-4A8F-A53F-1C7EAC961997</gtr:id><gtr:name>Harvard University</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/2C711771-B8F6-4CDF-9AC3-9FAB317463D9"><gtr:id>2C711771-B8F6-4CDF-9AC3-9FAB317463D9</gtr:id><gtr:name>University of Cape Town</gtr:name><gtr:address><gtr:line1>Private Bag</gtr:line1><gtr:line2>Rondebosch</gtr:line2><gtr:postCode>7700</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>South Africa</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/A6E6C042-46F9-434B-970F-5F9C8BCF6F1A"><gtr:id>A6E6C042-46F9-434B-970F-5F9C8BCF6F1A</gtr:id><gtr:name>PENTA Foundation</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/B8315305-3AE0-4833-BCEF-0539D3B31074"><gtr:id>B8315305-3AE0-4833-BCEF-0539D3B31074</gtr:id><gtr:name>Gilead</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/FA687C0B-0BA5-416F-9706-CC09EE9C9AB5"><gtr:id>FA687C0B-0BA5-416F-9706-CC09EE9C9AB5</gtr:id><gtr:name>Paediatric Emergency Research in the United Kingdom &amp; Ireland (PERUKI)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/58B69503-B9E3-43E3-AEB2-82D521E4C95E"><gtr:id>58B69503-B9E3-43E3-AEB2-82D521E4C95E</gtr:id><gtr:firstName>Diana</gtr:firstName><gtr:surname>Gibb</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MC_UU_12023%2F17"><gtr:id>07290A93-D55C-4D13-B04F-7648BF68167A</gtr:id><gtr:title>Paediatric Programme - HIV and other Diseases of Poverty.</gtr:title><gtr:status>Active</gtr:status><gtr:grantCategory>Intramural</gtr:grantCategory><gtr:grantReference>MC_UU_12023/17</gtr:grantReference><gtr:abstractText>Our studies aim to improve management of children with severe illnesses of poverty (predominantly HIV, Malaria, bacterial infections, TB) worldwide. We have 20 years experience of HIV in children, inintially in Europe, now mainly in Africa. In Europe, prevention of mother-to-child HIV transmission has reduced new infections in babies, but many children are now entering adolescence. Our research is finding out the best medicines with the fewest longterm side-effects, as children have to take treatment for life. In UK, we are starting a new study (AALPHI) to find out how HIV and its treatment affects young people entering adulthood. |Rollout of HIV treatment in Africa is increasing, bringing many questions about how best to do this in countries with few trained staff or health infrastructure. HIV-infected children have many other problems including malnutrition, tuberculosis, bacterial infections, malaria; without treatment, ~50% die before their second birhtday. We are undertaking large studies with colleagues in south/east African countries aimed at providing ways to enable more children to access HIV treatment. |Throughout Africa, death from malaria and other severe infections is unacceptably high, most occurring &amp;lt;24 hours after admission to hospital. Little attention has been paid to resuscitation with fluids. We are working with colleagues in Kenya to find out the best way to resuscitate these very sick children, particularly with malaria.</gtr:abstractText><gtr:technicalSummary>The CTU paediatric programme of trials and cohorts of childhood diseases of poverty - HIV, malaria, tuberculosis and sepsis - aims to generate evidence to inform policy and practice in both well-resourced and resource-limited countries worldwide, particularly Africa. |The PENTA (Paediatric European Network for treatment of AIDS, www.pentatrials.org) program (funding EU 1990-2015) undertakes cohorts and trials in ~15 countries in Europe, South America, Asia(Thailand) and Africa (Uganda) addressing questions on HIV-infection in children which cannot be extrapolated or assumed from adult studies. New trials aimed at older children/adolescents focus on strategies to maximise efficacy and adherence to antiretroviral therapy (ART) while minimising longterm toxicity (PENTA 16, 18 &amp;amp; 20 trials). Two trials recently completed: (1)PENTA 11, a trial of CD4-guided treatment interruptions (AIDS 2010) has 5 year follow-up ongoing; (2)PENPACT1: a 5-year trial of what treatment to start and when to switch will be presented at World AIDS 2010. |Individual patient meta-analyses of European cohort data address multiple questions, including informing trial design, facilitating recruitment and longterm follow-up during/after trials, comparisons between adults and children and pharmcovigilance information for the EMEA. The Childrens HIV Paediatric Study (CHIPS, a UK/Irish paediatric HIV cohort, www.chipscohort.org, DOH funding 1990-), contributes to the above and also provides annual feedback to inform national paedaitric HIV services. Recently (2012) a new cohort study of HIV-infected adolescents and HIV-negative controls has started recruitment. It will evaluate long-term health outcomes in these two groups, with a particular focus on neurodevelopment, quality of life and growth. |In Africa, large ongoing trials in Uganda, Zambia, Zimbabwe and South Africa (total ~2,500 children) are addressing multiple management questions including: when to start ART in children; when and whether ART can be stopped after early treatment; how to monitor children on ART; simplification of ART using fixed dose combination baby pills and once-daily dosing; whether cotrimoxaozole prophylaixs can be stopped in children on ART. Several trials have 2 or more randomisations (in factorial design), have multiple substudies (e.g. pharmacokinetics, adherence, co-morbidities tuberculosis, sepsis, malnutirition) and include additional social science and economic components. A new trial addressing ways to reduce early mortality in HIV-infected adults and children is planned. |In collaboration with Wellcome Trust centre, Kilifi, Kenya, FEAST (www.Feast.org, 2009-2011) is a large (3,600) pragmatic trial evaluating fluid resuscitation strategies in sick children in Uganda, Tansania and Kenya, predominantly due to malaria and sepsis. CTU plays a key role in design, analysis and mentoring. A new trial evaluating transfusion, antibiotic and prophylaxis strategies in sick anaemic children coming into hospital is in the planning stages (TRACT trial).</gtr:technicalSummary><gtr:fund><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2013-08-01</gtr:start><gtr:type>EXPENDITURE_ACTUAL</gtr:type><gtr:valuePounds>2201000</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Paediatric Emergency Research in the United Kingdom &amp; Ireland (PERUKI)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>PERUKI - the Paediatric Emergency Medicine research collaborative for the United Kingdom &amp;amp; Ireland</gtr:description><gtr:id>42491F90-6C16-4D6E-A831-F6F9E66C2C68</gtr:id><gtr:impact>Feasibility study for the CAP-IT trial; ongoing collaboration in the CAP-IT trial involving clinicians, nurses and pharmacists</gtr:impact><gtr:outcomeId>58b9b91bbf74f4.22243446-1</gtr:outcomeId><gtr:partnerContribution>Development of trial protocol and operational requirements</gtr:partnerContribution><gtr:piContribution>The CAP-IT trial has been developed in conjunction with the PERUKI network</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Cape Town</gtr:collaboratingOrganisation><gtr:country>South Africa, Republic of</gtr:country><gtr:description>Collaborative Initiative for Paediatric HIV Education and Research (CIPHER)</gtr:description><gtr:id>C35FEBAC-B7C2-4C1E-B32E-D53D4834F033</gtr:id><gtr:impact>Our team presented data from this collaboration at the UNAIDS Paediatric Reference Group meeting on 9 and 10 November 2016.
We also presented data at the &amp;quot;Estimating paediatric HIV and the need for ART meeting&amp;quot;, World Health Organization, in 2015</gtr:impact><gtr:outcomeId>58bea5babaab66.45413784-1</gtr:outcomeId><gtr:partnerContribution>Our partners have provided similar contributions.</gtr:partnerContribution><gtr:piContribution>The Collaborative Initiative for Paediatric HIV Education and Research (CIPHER) of the International AIDS Society (IAS) is aimed at optimizing clinical management and delivery of services to infants, children and adolescents affected by HIV in resource-limited settings through advocacy and research promotion. 

We have led the oversight and analysis of two key international individual patient data meta-analyses, on duration of first line, and epidemiology of adolescents. We participate in the Steering Committee for the collaboration, review grant applications submitted to the collaboration, and provide high level advice in terms of meeting planning.

Participation in CIPHER has also led to us being guest editor for a special issue of the Journal of the International AIDS Society on adolescent transition.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Gilead</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Gilead</gtr:description><gtr:id>F9AF31D0-F5EF-4947-B32D-94E94562EF3F</gtr:id><gtr:impact>Final protocol; fpfv planned Q2 2016; clinical, virology, immunology, pharmacokinetics</gtr:impact><gtr:outcomeId>56df11ea241617.17175794-1</gtr:outcomeId><gtr:partnerContribution>Review of protocol; provision of free drug</gtr:partnerContribution><gtr:piContribution>Design and conduct of trial protocol</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Harvard University</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>Harvard T.H. Chan School of Public Health</gtr:department><gtr:description>Collaborative Initiative for Paediatric HIV Education and Research (CIPHER)</gtr:description><gtr:id>9A0C1F1C-5438-451A-AF95-855F2FE094F5</gtr:id><gtr:impact>Our team presented data from this collaboration at the UNAIDS Paediatric Reference Group meeting on 9 and 10 November 2016.
We also presented data at the &amp;quot;Estimating paediatric HIV and the need for ART meeting&amp;quot;, World Health Organization, in 2015</gtr:impact><gtr:outcomeId>58bea5babaab66.45413784-2</gtr:outcomeId><gtr:partnerContribution>Our partners have provided similar contributions.</gtr:partnerContribution><gtr:piContribution>The Collaborative Initiative for Paediatric HIV Education and Research (CIPHER) of the International AIDS Society (IAS) is aimed at optimizing clinical management and delivery of services to infants, children and adolescents affected by HIV in resource-limited settings through advocacy and research promotion. 

We have led the oversight and analysis of two key international individual patient data meta-analyses, on duration of first line, and epidemiology of adolescents. We participate in the Steering Committee for the collaboration, review grant applications submitted to the collaboration, and provide high level advice in terms of meeting planning.

Participation in CIPHER has also led to us being guest editor for a special issue of the Journal of the International AIDS Society on adolescent transition.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>PENTA Foundation</gtr:collaboratingOrganisation><gtr:country>France, French Republic</gtr:country><gtr:description>PENTA Foundation</gtr:description><gtr:id>6905F6E8-A268-4CE0-8FB1-AC981751D466</gtr:id><gtr:impact>completion and publication of PENTA 11, 15 and PENTA 18 trials; completion of main and extended follow-up PENTA 16 trial; finalisation of PENTA 17 protocol; activation and co-ordination of PENTA 20</gtr:impact><gtr:outcomeId>FsjfLeVNvoh-1</gtr:outcomeId><gtr:partnerContribution>INSERM, France and PHPT, Thailand clinical trials units work collaboratively with MRC CTU at UCL on coordination of PENTA trials.</gtr:partnerContribution><gtr:piContribution>Scientific lead in writing project proposal. scientific leadership, coordination of trials and studies, coordinating role and speakers on PENTA training online and residential courses worldwide. Contribute to European PENTA guidelines.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Series of training videos for managing children on antiretroviral therapy</gtr:description><gtr:form>A broadcast e.g. TV/radio/film/podcast (other than news/press)</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>30094446-2820-4811-A1EB-9B0F3BAF1DC8</gtr:id><gtr:impact>We have produced a set of interactive training videos to teach paediatric HIV care. The videos were filmed mostly in a district hospital in Malawi and follow the management of children with HIV over time. They are designed to force students to make the kinds of clinical decisions they will face in their work. Topics include early infant diagnosis, ART initiation, common opportunistic infections, drug reactions and assessing possible treatment failure.

The videos have frequent stop points with questions which can be used to generate discussion. They are accompanied by detailed notes for teachers and trainers which can easily be adapted to different settings and guidelines. At present the videos are being used in PENTA (Paediatric European Network for the Treatment of AIDS) courses which are held around the world.

The films are available to watch and download for free on our Vimeo Channel, where the notes and scripts can also be downloaded. They vary in length from 3 minutes to 16 in length. At present 12 videos are complete. There will be an additional 8 videos uploaded in coming months.</gtr:impact><gtr:outcomeId>56d9570d53c947.32999963</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:url>http://www.ctu.mrc.ac.uk/resources/multimedia/arrow_videos_and_teaching_scripts/</gtr:url><gtr:year>2014,2015,2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Graphic novels on growing up with HIV (based on ARROW Young Lives research)</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>C18F43EB-68D3-4F88-B394-09395D586A3B</gtr:id><gtr:impact>We produced a series of 3 graphic novels to communicate the findings of the ARROW Young Lives social science sub-study. These novels explore what it is like to grow up with HIV in Uganda. The novels are available in English and Luganda.
The novels were distributed to study participants at a results meeting, and to clinic waiting rooms. They are also available online, and are being translated into different languages for use in other countries.</gtr:impact><gtr:outcomeId>56d9581a449611.71349505</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Study participants or study members</gtr:primaryAudience><gtr:url>http://www.ctu.mrc.ac.uk/resources/multimedia/arrow_graphic_novels/</gtr:url><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>AALPHI cognition</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>4935074A-612B-44EF-9350-DEE112B46D7C</gtr:id><gtr:impact>Talks at European AIDS Treatment Group (EATG) conference on cognition and anxiety/ depression in young people with HIV</gtr:impact><gtr:outcomeId>58bea8358d4a65.52139083</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Patients, carers and/or patient groups</gtr:primaryAudience><gtr:url>https://www.ageingwithhiv.com/</gtr:url><gtr:year>2017</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>CHIVA</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>29AEC08E-4413-435E-B2E8-B6416C5194A4</gtr:id><gtr:impact>Twice yearly contribution of lay text on the CHIPS study to the CHIVA Newsletter; yearly presentation of key findings from the CHIPS and AALPHI studies at the CHIVA national conference. Updating on results and ongoing PENTA trials

Improved reporting of patients to CHIPS, and general understanding of the CHIPS data and its importance. Recruitment of patients into PENTA trials</gtr:impact><gtr:outcomeId>UiRSqiT5Mbj</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2006,2007,2008,2009,2010</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>46842</gtr:amountPounds><gtr:country>Switzerland, Swiss Confederation</gtr:country><gtr:currCode>USD</gtr:currCode><gtr:currCountryCode>Ecuador</gtr:currCountryCode><gtr:currLang>es_EC</gtr:currLang><gtr:description>CIPHER Cohort Collaborative Projects ($ 142964; 2014 - 2015)</gtr:description><gtr:end>2018-12-02</gtr:end><gtr:fundingOrg>International AIDS Society (IAS)</gtr:fundingOrg><gtr:id>DCC95861-8706-4F04-B656-A5FCEE5F28B1</gtr:id><gtr:outcomeId>58bea6bb04b974.49295896</gtr:outcomeId><gtr:sector>Learned Society</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>4617034</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>EUR</gtr:currCode><gtr:currCountryCode>Austria</gtr:currCountryCode><gtr:currLang>de_AT</gtr:currLang><gtr:department>European and Developing Countries Clinical Trials Partnership</gtr:department><gtr:description>CHAPAS 3: Expanding the Availability of Fixed Dose Combination Antiretroviral Formulations for First-line Treatment of HIV-infected Children - the Children with HIV in Africa Pharmacokinetics and Acceptability/Adherence of Simple Antiretroviral Regimens</gtr:description><gtr:end>2014-01-02</gtr:end><gtr:fundingOrg>Sixth Framework Programme (FP6)</gtr:fundingOrg><gtr:id>5DA14F52-3005-4AC1-866A-5D9CBB72E286</gtr:id><gtr:outcomeId>58c81606b84125.98950577</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Influence on WHO Guideline on Paediatric emergency triage, assessment and treatment: Care of critically ill children</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:guidelineTitle>WHO Guideline on Paediatric emergency triage, assessment and treatment: Care of critically ill children</gtr:guidelineTitle><gtr:id>6D9EF2AF-2C05-4119-8F38-68A8DDA76A75</gtr:id><gtr:impact>The new WHO guidelines recommend that rapid fluid resuscitation is not used for children with 1 or 2 signs of shock, following the results of the FEAST trial. However, they still recommend (more conservative) fluid resuscitation for children with all three signs of shock.
FEAST found that rapid fluid resuscitation was associated with excess mortality for children with any definition of shock. The new guidelines are progress, but do not completely accord with the FEAST recommendations.</gtr:impact><gtr:outcomeId>56d8696cb42953.04813542</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type><gtr:url>http://apps.who.int/iris/bitstream/10665/204463/1/9789241510219_eng.pdf?ua=1</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>ARROW influence on WHO Guidelines on When to Start ART (2015)</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:guidelineTitle>GUIDELINE ON WHEN TO START ANTIRETROVIRAL THERAPY AND ON PRE-EXPOSURE PROPHYLAXIS FOR HIV</gtr:guidelineTitle><gtr:id>E09B8DA3-F5BE-4900-8B27-E98A80012C67</gtr:id><gtr:impact>The new WHO guidelines cite the ARROW results, saying &amp;quot;Expanding ART services for children will require strategies to improve retention in care and to support adherence. Careful clinical monitoring remains essential to assess the risk of treatment failure, but lack of laboratory monitoring should not be a barrier to initiating ART.&amp;quot; 
ARROW showed that children on ART had excellent outcomes with clinical monitoring, and that routine laboratory monitoring was not cost-effective in most circumstances. It is important that this is acknowledged in the WHO guidelines, as there is a move towards requiring routine viral load monitoring, which could act as a barrier to access for children in rural areas in low-income countries.</gtr:impact><gtr:outcomeId>56d9557bb6cc97.62949033</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type><gtr:url>http://apps.who.int/iris/bitstream/10665/186275/1/9789241509565_eng.pdf?ua=1</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>HYPNet mortality audit citation in US paed guidelines</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:guidelineTitle>Guidelines for tPanel on Antiretroviral Therapy and Medical Management of HIV-Infected Children. Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection. 2016. Available at http://aidsinfo.nih.gov/contentfiles/lvguidelines/pediatricguidelines.pdfhe Use of Antiretroviral Agents in Pediatric HIV Infection</gtr:guidelineTitle><gtr:id>2357A3C5-922F-495E-942C-63A120D6418C</gtr:id><gtr:outcomeId>58beba45930705.89231567</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs><gtr:productOutput><gtr:clinicalTrial>true</gtr:clinicalTrial><gtr:description>All young people enrolled in this clinical trial evaluating the role of Short Cycle Therapy (5 days on, 2 days off) in the management of HIV infection will be followed until July 2014. Young people continued to be followed on their randomised treatment, where appropriate, in a 2 year extended follow-up period until July 2016. Results were presented at CROI 2017</gtr:description><gtr:id>60405953-FE53-460F-A137-67F05721DD2C</gtr:id><gtr:impact>Results were presented at CROI 2017. A further trial is planned to look at the possibility of a short course therapy in settings where viral loads are measured annually.</gtr:impact><gtr:outcomeId>TKMwg1M8zQz</gtr:outcomeId><gtr:stage>Late clinical evaluation</gtr:stage><gtr:status>Closed</gtr:status><gtr:title>BREATHER - PENTA 16</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:url>http://pentatrials.org</gtr:url><gtr:yearDevCompleted>2010</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:clinicalTrial>true</gtr:clinicalTrial><gtr:description>SMILE: Strategy for Maintenance of HIV suppression with elvitegravir+darunavir / ritonavir in children (PENTA 17). A two-arm, Phase 2/3 multicentre, open-label, randomised study evaluating safety and antiviral effect of current standard antiretroviral therapy compared to elvitegravir (EVG) administered with darunavir/ritonavir (DRV/r) in HIV-1 infected, virologically suppressed paediatric participants. FPFV enrolled June 2016. Funding from EU, PENTA Foundation, Gilead, Janssen, INSERM.</gtr:description><gtr:id>9C77FFAC-0360-435E-BFEF-3B66F6B1DCD9</gtr:id><gtr:impact>n/a</gtr:impact><gtr:outcomeId>545ca1fb093420.60768191</gtr:outcomeId><gtr:stage>Market authorisation</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>SMILE - PENTA 17</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:url>http://penta-id.org</gtr:url><gtr:yearDevCompleted>2016</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:clinicalTrial>true</gtr:clinicalTrial><gtr:description>Efficacy, safety and impact on antimicrobial resistance of duration and dose of amoxicillin treatment for young children with Community Acquired Pneumonia (CAP): a randomIsed controlled Trial (CAP-IT). Funded by NIHR HTA. Recruitment started Q1 2017. Collaboration with PERUKI, SGUL, Universities of Bristol, Southampton, Oxford.</gtr:description><gtr:id>92B3AAC6-7C0B-45B0-8B62-9A4E22897805</gtr:id><gtr:impact>Feasibility study completed. Pilot study will include validation of saliva swabs against nasopharyngeal swabs for identification of S.pneumoniae and identification of changes in antibiotic resistance.</gtr:impact><gtr:outcomeId>56df0ba76b1999.43571633</gtr:outcomeId><gtr:stage>Refinement.  Clinical</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>CAP-IT - amoxicillin</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:ukcrnIsctnId>HTA 13/88/11</gtr:ukcrnIsctnId><gtr:yearDevCompleted>2016</gtr:yearDevCompleted></gtr:productOutput></gtr:productOutputs><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>008292E7-B3C3-43C9-8F0A-4047806719BB</gtr:id><gtr:title>Clinical Status of Adolescents with Perinatal HIV at Transfer to Adult Care in the UK/Ireland.</gtr:title><gtr:parentPublicationTitle>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d66b4398b1376bf2dece8528b69a272c"><gtr:id>d66b4398b1376bf2dece8528b69a272c</gtr:id><gtr:otherNames>Collins IJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1058-4838</gtr:issn><gtr:outcomeId>5a9ca503d0bbb0.85703138</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2B702423-11FE-4BC1-BFB5-12551365C612</gtr:id><gtr:title>Inequality in outcomes for adolescents living with perinatally acquired HIV in sub-Saharan Africa: a Collaborative Initiative for Paediatric HIV Education and Research (CIPHER) Cohort Collaboration analysis.</gtr:title><gtr:parentPublicationTitle>Journal of the International AIDS Society</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/319fa2b516564e195d2ad4bd070aba90"><gtr:id>319fa2b516564e195d2ad4bd070aba90</gtr:id><gtr:otherNames>CIPHER Global Cohort Collaboration</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>1758-2652</gtr:issn><gtr:outcomeId>5a9ca724179933.61354138</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8A088D3C-0EC9-4FA9-B8F5-711544886007</gtr:id><gtr:title>The epidemiology of adolescents living with perinatally acquired HIV: A cross-region global cohort analysis.</gtr:title><gtr:parentPublicationTitle>PLoS medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8fc47edf07612b581b9ef9bc9771ad7a"><gtr:id>8fc47edf07612b581b9ef9bc9771ad7a</gtr:id><gtr:otherNames>Collaborative Initiative for Paediatric HIV Education and Research (CIPHER) Global Cohort Collaboration</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>1549-1277</gtr:issn><gtr:outcomeId>5a9ca6faf350e8.12366721</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C1395C44-BABC-4CDC-B85C-16539DA81CC8</gtr:id><gtr:title>Growing up with perinatal HIV: changes in clinical outcomes before and after transfer to adult care in the UK.</gtr:title><gtr:parentPublicationTitle>Journal of the International AIDS Society</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1816521cf70493060b185b80207903df"><gtr:id>1816521cf70493060b185b80207903df</gtr:id><gtr:otherNames>Judd A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1758-2652</gtr:issn><gtr:outcomeId>5a9ca52a9eb0b8.64982354</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E2947A20-B6BF-4EAF-8A5B-B1A2FB1BE3FF</gtr:id><gtr:title>Paediatric European Network for Treatment of AIDS (PENTA) guidelines for treatment of paediatric HIV-1 infection 2015: optimizing health in preparation for adult life.</gtr:title><gtr:parentPublicationTitle>HIV medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3da9d74f94d2e484bd71b0b6e6e2f9d6"><gtr:id>3da9d74f94d2e484bd71b0b6e6e2f9d6</gtr:id><gtr:otherNames>Bamford A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>1464-2662</gtr:issn><gtr:outcomeId>56d7349cb7e129.35867526</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C5B3382A-6638-472A-B07D-34B316E3F637</gtr:id><gtr:title>Is nevirapine dose-escalation appropriate in young, African, HIV-infected children?</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/20b4fd879ac1191d42647203da1ba638"><gtr:id>20b4fd879ac1191d42647203da1ba638</gtr:id><gtr:otherNames>Fillekes Q</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>56e166247625b2.19045478</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>59A8F1F8-1E33-4092-A3FF-0AEF936699F8</gtr:id><gtr:title>Potential future impact of a partially effective HIV vaccine in a southern African setting.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/183477fd03e755ffd093359907ffb43e"><gtr:id>183477fd03e755ffd093359907ffb43e</gtr:id><gtr:otherNames>Phillips AN</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>56e04f6d8e83e8.14566545</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>790329C8-9692-4607-AF7A-9834213175D4</gtr:id><gtr:title>Acceptability of lopinavir/r pellets (minitabs), tablets and syrups in HIV-infected children.</gtr:title><gtr:parentPublicationTitle>Antiviral therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/24458c08d0d487d652c1a2bfe83e59bc"><gtr:id>24458c08d0d487d652c1a2bfe83e59bc</gtr:id><gtr:otherNames>Kekitiinwa A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1359-6535</gtr:issn><gtr:outcomeId>5a3244cc3265f1.26994575</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>74BF2A61-C4E1-425E-A28A-3E8A1476128E</gtr:id><gtr:title>Cost-effectiveness of HIV drug resistance testing to inform switching to second line antiretroviral therapy in low income settings.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1bfd7cf3d8aacf5a4a193b1e91e7ea59"><gtr:id>1bfd7cf3d8aacf5a4a193b1e91e7ea59</gtr:id><gtr:otherNames>Phillips A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>56e04f6d663e50.62866167</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E5FE8ACE-E26F-4456-B872-E1B226028519</gtr:id><gtr:title>Anthropometric measurements and lipid profiles to detect early lipodystrophy in antiretroviral therapy experienced HIV-infected children in the CHAPAS-3 trial.</gtr:title><gtr:parentPublicationTitle>Antiviral therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0e3d78c5672e7bdca46d5ced1d2d76a0"><gtr:id>0e3d78c5672e7bdca46d5ced1d2d76a0</gtr:id><gtr:otherNames>Musiime V</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1359-6535</gtr:issn><gtr:outcomeId>56e1662456c5b3.59200524</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>32007E6F-AEC1-4D5B-AF6A-89C4EA44B554</gtr:id><gtr:title>Single Genome Analysis for the Detection of Linked Multiclass Drug Resistance Mutations in HIV-1-Infected Children After Failure of Protease Inhibitor-Based First-Line Therapy.</gtr:title><gtr:parentPublicationTitle>Journal of acquired immune deficiency syndromes (1999)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d105be070a3190725488c10ec8251c9c"><gtr:id>d105be070a3190725488c10ec8251c9c</gtr:id><gtr:otherNames>Lange CM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1525-4135</gtr:issn><gtr:outcomeId>56e180dd90df14.92232052</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>003F08B8-882D-4D92-8624-45B89BE1F5BE</gtr:id><gtr:title>Reactivity of routine HIV antibody tests in children who initiated antiretroviral therapy in early infancy as part of the Children with HIV Early Antiretroviral Therapy (CHER) trial: a retrospective analysis.</gtr:title><gtr:parentPublicationTitle>The Lancet. Infectious diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/38a8b7109cdc0d70aad0062ab59d94c5"><gtr:id>38a8b7109cdc0d70aad0062ab59d94c5</gtr:id><gtr:otherNames>Payne H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1473-3099</gtr:issn><gtr:outcomeId>56e180dd71f0f1.78523252</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BB3DF983-23F7-41D9-A7E2-1D7955EE12ED</gtr:id><gtr:title>The Lablite project: a cross-sectional mapping survey of decentralized HIV service provision in Malawi, Uganda and Zimbabwe.</gtr:title><gtr:parentPublicationTitle>BMC health services research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1b72ee7fa5cffa46951b87bbea236715"><gtr:id>1b72ee7fa5cffa46951b87bbea236715</gtr:id><gtr:otherNames>Chan AK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1472-6963</gtr:issn><gtr:outcomeId>56e04f6cc23cd5.83219647</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>84679C55-E4A2-4114-A9FE-C1CFFE006F87</gtr:id><gtr:title>Long-term virological outcome in children on antiretroviral therapy in the UK and Ireland.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8f28f13ce25a4c90dd0814c4134d4bee"><gtr:id>8f28f13ce25a4c90dd0814c4134d4bee</gtr:id><gtr:otherNames>Duong T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>5a32593409f600.12378739</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MC_UU_12023/17</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>03BA7BC9-C251-48FC-8EA9-5F7414A63FEE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Infection</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>9A8BEDCC-D902-4C9A-8CCF-C974265EA3FB</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>2.4  Surveillance and distribution</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>7135039D-2DB0-4D41-87B3-FA1C8D38E133</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>6.1  Pharmaceuticals</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>